Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

655
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
655
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influencing factors in knee kinematics following posteriorly stabilized knee arthroplasty: a comprehensive analysis.

Acta orthopaedica Belgica·2025
Same author

Trends For Smaller Medical Journals.

Acta clinica Belgica·2016
Same author

Temperature dependence of the electronic structure of semiconductors and insulators.

The Journal of chemical physics·2015
Same author

Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial.

British journal of cancer·2015
Same author

[Update on the management of acute viral bronchiolitis: proposed guidelines of Grand Ouest University Hospitals].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2013
Same author

[Management of bronchiolitis in general practice and determinants of treatment being discordant with guidelines of the HAS].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2013

Related Experiment Video

Updated: May 5, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K

New developments in antiplatelet and antithrombotic therapy

M Verstraete1

  • 1Center for Molecular and Vascular Research, University of Leuven, Belgium.

European Heart Journal
|November 1, 1995
PubMed
Summary

New antiplatelet and anticoagulant agents are being developed to improve thrombosis treatment. Research focuses on novel inhibitors targeting platelet receptors and thrombin, with some showing promise in clinical trials for antithrombotic therapy.

Area of Science:

  • Pharmacology and Therapeutics
  • Hematology and Thrombosis Research

Background:

  • Established antiplatelet agents (aspirin, ticlopidine, dipyridamole) and anticoagulants (vitamin K antagonists, heparins) are in clinical use.
  • Ongoing research aims to develop more effective antiplatelet and anticoagulant therapies for thrombosis management.

Purpose of the Study:

  • To review the development and clinical application of novel antiplatelet and anticoagulant agents.
  • To highlight advancements in targeting platelet aggregation and coagulation pathways for antithrombotic therapy.

Main Methods:

  • Review of existing and emerging antiplatelet drugs, including clopidogrel, thromboxane synthase inhibitors, and receptor blockers.
  • Examination of novel anticoagulants, such as direct thrombin inhibitors and factor Xa inhibitors, tested in preclinical and clinical settings.

More Related Videos

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.2K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K

Related Experiment Videos

Last Updated: May 5, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.2K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K
  • Discussion of monoclonal antibodies and synthetic inhibitors targeting platelet glycoprotein receptors.

    • Main Results:

    • Development of clopidogrel as a ticlopidine analogue with improved safety profile.
    • Clinical progress with direct thrombin inhibitors (recombinant hirudin, hirulog, argatroban) as effective antithrombotic agents.
    • Preclinical testing of various novel anticoagulants, including tissue factor pathway inhibitors and factor Xa inhibitors.

    Conclusions:

    • Significant advancements have been made in developing novel antiplatelet and anticoagulant agents.
    • Direct thrombin inhibitors show clinical efficacy in patients, while other novel anticoagulants require further investigation.
    • Continued research into receptor antagonists and inhibitors offers potential for improved antithrombotic strategies.